Abstract
Over the past 2 decades the surgical approach to primary breast carcinoma has changed remarkably, passing from radical mastectomy to quadrantectomy and when possible, to a simple tumorectomy. Nevertheless, the dissection of the axillary nodes has not changed due to the unanimous agreement that the status of axillary lymph nodes is the key criterion for assessing prognosis of breast cancer patients. Clinically uninvolved axillary nodes are always dissected despite the fact that several studies1–5 have shown the irrelevant therapeutic role of axillary node dissection as a “prophylactic” procedure and that surgery on these nodes is responsible for the vast majority of post surgical complications. However, lymph node dissection is still unavoidable today in order to obtain the prognostic information required to plan the future therapeutical treatment of the patient.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Cancer research campaign (King’s/Cambridge) trial for early breast cancer. A detailed update at the tenth year. Cancer Research Campaign Working Party, Lancet 1: 55 (1980).
B. Fisher, N. Wolmark, C. Redmond, M. Deutsch, and E.R. Fisher, Findings from NSABP B-04: Comparison of radical mastectomy with alternative treatments. II. The clinical and biologic significance of medical-central breast cancer, Cancer 48: 1863 (1981).
B. Fisher. A critical commentary on the evaluation of breast cancer surgery, in: Clinical Trials in Cancer Medicine, eds. U. Veronesi and G. Bonadonna. Ac.Press Inc., (1985).
B. Fisher, C. Redmond, E.R. Fisher, M. Bauer, N. Wolmark, L. Wicherham, M. Deutsch, E. Montague, R. Margolese, and R. Foster, Ten-year resulys of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation, N. Engl. J. Med. 312: 674 (1985).
J.P. Lythgoe, I. Leck, and R. Swindell, Manchester regional breast study. Preliminary results, Lancet 1: 744 (1978).
N. Cascinelli, M.I. Colnaghi, F. Rilke, S. Menard, R. Bufalino, S. Andreola, M. Greco, L. Mascheroni, and A. Testori, Comparison of the prognostic information of breast cancer patients given by histologic examination of axillary nodes and evaluation of two biological indicators on primary tumor, Submitted (1992).
W.J. Gullick, 4. The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer, Int. J. Cancer 46 Suppl. 5: 55 (1990).
E. Peles, S.S. Bacus, R.A. Koski, H.S. Lu, D. Wen, S.G. Ogden, R. Ben Levy, and Y. Yarden, Isolation of the neu/HER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells, Cell 69: 205 (1992).
T.J. Perren, c-erbB-2 oncogene as a prognostic marker in breast cancer, Br. J. Cancer 63: 328 (1991).
W.J. Gullick, S.B. Love, C. Wright, D.M. Barnes, B. Gusterson, A.L. Harris, and D.G. Altman, c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes, Br. J. Cancer 63: 434 (1991).
F. Rilke, M.I. Colnaghi, N. Cascinelli, S. Andreola, M.T. Baldini, R. Bufalino, G. Delia Porta, S. Ménard, M.A. Pierotti, and A. Testori, Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors, Int. J. Cancer 49: 44 (1991).
V. Castronovo, C. Colin, A.P. Claysmith, P.H.S. Chen, E. Lifrange, R. Lambotte, H. Krutzsch, L.A. Liotta, and M.E. Sobel, Immunodetection of the metastasis-associated laminin receptor in human breast cancer cells obtained by fine-needle aspiration biopsy, Am. J. Pathol. 137: (1990).
S. Martignone, S. Ménard, R. Bufalino, N. Cascinelli, R. Pellegrini, E. Tagliabue, S. Andreola, F. Rilke, and M.I. Colnaghi, Prognostic significance of the 67 KDa laminin receptor expression in breast carcinomas, Submitted (1992).
S. Martignone, R. Pellegrini, E. Villa, N.N. Tandon, A. Mastroianni, E. Tagliabue, S. Menard, and M.I. Colnaghi, Characterization of two monoclonal antibodies directed against the 67KDa high affinity laminin receptor and application for the study of breast carcinoma progression, Clin. Exp. Metast. In press (1992).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer Science+Business Media New York
About this chapter
Cite this chapter
Colnaghi, M.I. (1994). The Simultaneous Expression of c-erbB-2 Oncoprotein and Laminin Receptor on Primary Breast Tumors has a Predicting Potential Analogous to that of The Lymph Node Status. In: Ceriani, R.L. (eds) Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment. Advances in Experimental Medicine and Biology, vol 353. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2443-4_14
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2443-4_14
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6038-4
Online ISBN: 978-1-4615-2443-4
eBook Packages: Springer Book Archive